SPOTLIGHT -
Vancouver, British Columbia-An $855 million deal will unite verteporfin (Visudyne) developer QLT Inc. and Atrix Laboratories Inc. to build QLT's business and accelerate strategic initiatives.
CLOSE study offers updated surgical classification for treating large full-thickness macular holes
Commercial real estate and your practice, part two with Colin Carr
Smart contact lens that diagnoses and treats glaucoma
Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)
Glaucoma 360: Home tonometry - worth the pressure?
Glaucoma 360: An update on IOLs - when and how to use them